[A18-75] Semaglutide (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V
Last updated 01.02.2019
Project no.:
A18-75
Commission:
Commission awarded on 30.10.2018 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Digestion, metabolism and hormones
Type 2 diabetes mellitus
Added benefit neither proven for monotherapy nor in combination with other blood-glucose lowering drugs; analyses of the SUSTAIN 6 study additionally presented not meaningfullly interpretable
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Accompanying information| Project no. | Title | Status |
|---|---|---|
| A20-93 | Semaglutide (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V (new scientific findings) | Commission completed |
Federal Joint Committee (G-BA)
2019-07-04 A G-BA decision was published.